Guideline for the diagnosis and management of myelofibrosis

British Journal of Haematology

Volumn 158, Issue 4, 2012, Pages 453-471

  Reilly, John T ^a   Mcmullin, Mary Frances ^b   Beer, Philip A ^c   Butt, Nauman ^d   Conneally, Eibhlean ^e   Duncombe, Andrew ^f   Green, Anthony R ^g   Michaeel, N George ^h   Gilleece, Marie H ⁱ   Hall, Georgina W ^j   Knapper, Steven ^k   Mead, Adam ^j   Mesa, Ruben A ^l   Sekhar, Mallika ^m   Wilkins, Bridget ^h   Harrison, Claire N ^h  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d WIRRAL UNIVERSITY TEACHING HOSPITAL   (United Kingdom)

^e ST JAMES S HOSPITAL   (Ireland)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁱ ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^j OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^k UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^l MAYO CLINIC   (United States)

^m ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Myelofibrosis; Myeloproliferative disorders; Transplantation; Treatment

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; ANDROGEN; AZACITIDINE; BCR ABL PROTEIN; BUSULFAN; CLADRIBINE; DANAZOL; FLUDARABINE; HEMOGLOBIN; HYDROXYUREA; IRON CHELATING AGENT; JANUS KINASE 2; JANUS KINASE INHIBITOR; LENALIDOMIDE; LYMPHOCYTE ANTIBODY; MELPHALAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON ALPHA2A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISOLONE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; ARTIFICIAL EMBOLISM; AUTOLOGOUS STEM CELL TRANSPLANTATION; BCR ABL1 GENE; BONE MARROW SUPPRESSION; CANCER SCREENING; CHILD HEALTH; CHOLESTATIC HEPATITIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMORBIDITY; CONSERVATIVE TREATMENT; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; DONOR LYMPHOCYTE INFUSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; EXTRAMEDULLARY HEMATOPOIESIS; FLUID RETENTION; GENE; GENE REARRANGEMENT; GRAFT VERSUS HOST REACTION; HEALTH STATUS; HEPATOMEGALY; HIRSUTISM; HUMAN; IRRADIATION; JAK2 GENE; LIBIDO; LIVER FUNCTION TEST; LIVER TUMOR; LOW DRUG DOSE; MOLECULAR DIAGNOSIS; MPL GENE; MYELOABLATIVE CONDITIONING; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PATIENT MONITORING; PDGFRA GENE; PDGFRB GENE; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; REDUCED INTENSITY CONDITIONING; SIDE EFFECT; SPLENECTOMY; SPLENIC ARTERY EMBOLIZATION; SPLENOMEGALY; SURVIVAL; TET GENE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT DURATION; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ANEMIA; BONE MARROW TRANSPLANTATION; ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JANUS KINASES; PRIMARY MYELOFIBROSIS; PROGNOSIS; SPLENECTOMY;

EID: 84864300766     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09179.x     Document Type: Article

References (123)

1. Abelsson, J., Merup, M., Birgegård, G., Weisbjerrum, O., Brinch, L., Brune, M., Johansson, P., Kauppila, M., Lenhoff, S., Liljeholm, M., Malm, C., Remes, K., Vindelöv, L. & Andréasson, B. (2011) The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplantation (in press).
2. Alexanian, R., Nadell, J. & Alfrey, C. (1972) Oxymetholone treatment for the anaemia of bone marrow failure. Blood, 40, 353-365.
3. Altura, R.A., Head, D.R. & Wang, W.C. (2000) Long-term survival of infants with idiopathic myelofibrosis. British Journal of Haematology, 109, 459-462.
4. Alvarez-Larran, A., Abraldes, J.G., Cervantes, F., Hernandez-Guerra, M., Vizzutti, F., Miquel, R., Gilabert, R., Giusti, M., Garcia-Pagan, J.C. & Bosch, J. (2005) Portal hypertension secondary to myelofibrosis: a study of three cases. American Journal of Gastroenterology, 100, 2355-2358.
5. Anderson, J.E., Tefferi, A., Craig, F., Holmberg, L., Channcey, T., Appelbaum, F.R., Guardiola, P., Callander, N., Freytes, C., Gazitt, Y., Razvillas, B. & Deeg, H.J. (2001) Myeloablation and autologous peripheral blood stem cell rescue results in hematolgic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood, 98, 586-593.
6. Angermayr, B., Cejna, M., Schoder, M., Wrba, F., Valent, P., Gangl, A. & Peck-Radosavljevic, M. (2002) Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood, 99, 4246-4247.
7. Bacigalupo, A., Soraru, M., Dominietto, A., Pozzi, S., Geroldi, S., Van Lint, M.T., Ibatici, A., Raiola, A.M., Frassoni, F., De Stefano, F., Verdiani, S., Casarino, L. & Barosi, G. (2010) Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplantation, 45, 458-463.
8. Ballen, K.K., Shrestha, S., Sobocinski, K.A., Zhnag, M.J., Bashey, A., Bolwell, B.J., Cervantes, F., Devine, S.M., Gale, R.P., Gupta, V., Hahn, T.E., Hogan, W.J., Kröger, N., Litzow, M.R., Marks, D.I., Maziarz, R.T., McCarthy, P.L., Schiller, G., Schouten, H.C., Roy, V., Wiernik, P.H., Hovowitz, M.M., Giralt, S.A. & Arora, M. (2010) Outcome of transplantation for myelofibrosis. Biology of Blood and Marrow Transplantation, 16, 358-367.
9. Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.J., Kröger, N., Mesa, R., McMillan, M.F., Pardanani, H., Passamonti, F., Vannucchi, A.M., Reiter, R., Silver, R.T., Verstovsek, S. & Tefferi, A. (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clincal Oncology, 29, 761-770.
10. Barosi, G., Ambrosetti, A., Buratti, A., Finelli, C., Liberato, N.L., Quaglini, S., Ricetti, M.M., Visani, G., Tura, S. & Ascari, E. (1993) Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia, 7, 200-206.
11. Barosi, G., Ambrosetti, A., Centra, A., Falcone, A., Finelli, C., Foa, P., Grossi, A., Guarnone, R., Rupoli, S., Luciano, L., Petti, M.C., Polgliani, E., Russo, D., Ruggeri, M. & Quaglini, S. (1998) Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood, 91, 3630-3636.
12. Barosi, G., Bergamaschi, G., Marchetti, M., Vannucchi, A.M., Guglielmelli, P., Antonioli, E., Massa, M., Rosti, V., Campanelli, R., Villani, L., Viarengo, G., Gattoni, E., Gerli, G., Specchia, G., Tinelli, C., Rambaldi, A. & Barbui, T. (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood, 110, 4030-4036.
13. Barosi, G., Mesa, R.A., Thiele, J., Cervantes, F., Campbell, P.J., Verstovsek, S., Dupriez, B., Levine, R.L., Passamonti, F., Gotlib, J., Reilly, J.T., Vannucchi, A.M., Hanson, C.A., Solberg, L.A., Orazi, A. & Tefferi, A. (2008) Proposed criteria for the diagnosis of post-polycythaemia and post-essential thrombocythemia myelofibrosis: a consensus statement from the Onternational Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leukemia, 22, 437-438.
14. Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H., Kiladijan, J.J., Lengfelder, E., Mesa, R., McMullin, M.F., Passamonti, F., Reilly, J.T., Vannucchi, A.M. & Barbui, T. (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 148, 961-963.
15. Bartlett, R.P., Greipp, P.R., Tefferi, A., Cupps, R.E., Mullan, B.P. & Trastek, V.F. (1995) Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Mayo Clinical Proceedings, 70, 1161-1164.
16. Beer, P.A., Campbell, P.J. & Green, A.R. (2010) Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurements of serum lactate dehydrogenase. Haematologica, 95, 1960-1963.
17. Beer, P.A., Erber, W.N., Campbell, P.J. & Green, A.R. (2011) How I treat essential thrombocythemia. Blood, 117, 1472-1482.
18. Benjamini, O., Koren-Michowitz, M., Amariglio, N., Kröger, N., Nagler, A. & Shimoni, A. (2008) Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia, 22, 1961-1963.
19. Berneman, Z.N., Anguille, S., Van Marck, V., Schroyens, W.A. & Van Tendeloo, V.F. (2010) Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis. British Journal of Haematology, 149, 152-155.
20. Besa, E.C., Nowell, P.C., Geller, N.L. & Gardner, F.H. (1982) Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer, 49, 308-313.
21. Bhakhri, B.K. & Debata, P.K. (2010) Nutritional rickets presenting with myelofibrosis. Indian Journal of Pediatrics, 77, 1437-1439.
22. Bouabdallah, R., Coso, D., Gonzague-Casabianca, L., Alzieu, C., Resbeut, M. & Gastaut, J.A. (2000) Safety and efficacy of splenic irradiation in the treatment of patients with idiopathic myelofibrosis: a report on 15 patients. Leukaemia Research, 24, 491-495.
23. Brubaker, L.H., Brière, J., Laszlo, J., Kraut, E., Landaw, S.A., Peterson, P., Goldberg, J. & Donovan, P. (1982) Treatment of anaemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Archives of Internal Medicine, 142, 1533-1537.
24. Byrne, J.L., Beshti, H., Clark, D., Ellis, I., Haynes, A.P., Das-Gupta, E. & Russell, N.H. (2000) Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect. British Journal of Haematology, 108, 430-433.
25. Campbell, P.J. & Green, A.R. (2006) The myeloproliferative disorders. New England Journal of Medicine, 355, 2452-2466.
26. Campbell, P.J., Griesshammer, M., Döhner, K., Döhner, H., Kusec, R., Hasselbalch, H.C., Larsen, T.S., Pallisgaard, N., Giraudier, S., le Bousse-Kerdiles, M.C., Desterke, C., Guerton, B., Dupriez, B., Bordessoule, D., Fenaux, P., Kiladjian, J.J., Viallard, J.F., Brière, J., Harriosn, C.N., Green, A.R. & Reilly, J.T. (2006) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood, 107, 2098-2100.
27. Cervantes, F., Hernandez-Boluda, J.C., Alvarez, A., Nadal, E. & Montserrat, E. (2000) Danazol treatment of idiopathic myelofibrosis with severe anaemia. Haematologica, 85, 595-599.
28. Cervantes, F., Alvarez-Larran, A., Hemandez-Boluda, J.C., Sureda, A., Torrebadell, M. & Monserrat, E. (2004) Erythropioietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients with review of the literature. British Journal of Haematology, 127, 399-403.
29. Cervantes, F., Alvarez-Larran, A., Domingo, A., Arellano-Rodrigo, E. & Montserrat, E. (2005) Efficacy and tolerability of danazol as a treatment for the anaemia of meylofibrosis with myeloid metaplasia: long-term results in 30 patients. British Journal of Haematology, 129, 771-775.
30. Cervantes, F., Alvarez-Larrán, A., Arellano-Rodrigo, E., Granell, M., Domingo, A. & Montserrat, E. (2006a) Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis ina series of 155 patients from a single institution. Leukemia, 20, 55-60.
31. Cervantes, F., Alvarez-Larran, A., Hernandez-Boluda, J.C., Sureda, A., Torrebadell, M. & Montserrat, E. (2006b) Darbepoietin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. British Journal of Haematology, 134, 184-186.
32. Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. & Tefferi, A. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 2895-2901.
33. Chang, J.C. & Gross, H.M. (1988) Remission of chronic idiopathic myelofibrosis to busulfan treatment. American Journal of Medical Science, 295, 472-476.
34. Ciurea, S.O., de Lima, M., Giralt, S., Saliba, R., Bueso-Lamos, C., Anderrson, B.S., Hosing, C.M., Verstovsek, S., Champlin, R.E. & Popat, U. (2010) Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biology of Blood and Marrow Transplantation, 16, 555-559.
35. Daly, A., Song, K., Nevill, T., Nantel, S., Toze, C., Hogge, D., Forrest, D., Lavoie, J., Sutherland, H., Shepherd, J., Hasegawa, W., Lipton, J., Messner, H. & Kiss, T. (2003) Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplantation, 32, 35-40.
36. Deeg, H.J., Gooley, T.A., Flowers, M.E., Sale, G.E., Slattery, J.T., Anasetti, C., Chauncey, T.R., Doney, K., Georges, G.E., Kiem, H.P., Martin, P.J., Petersdorf, E.W., Radich, J., Sanders, J.E., Sandmaier, B.M., Warren, E.H., Witherspoon, R.P., Storb, R. & Appelbaum, F.R. (2003) Allogeneic hematopoietic stem cell transplanation for myelofibrosis. Blood, 102, 3912-3918.
37. Devine, S.M., Hoffman, R., Verma, A., Shah, R., Bradlow, B.A., Stock, W., Maynard, V., Jessop, E., Peace, D., Huml, M., Thomason, D., Chen, Y.H. & van Besien, K. (2002) Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood, 99, 2255-2258.
38. Ditschkowski, M., Beelen, D.W., Trenschel, R., Koldehoff, M. & Elmaagacli, A.H. (2004) Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplantation, 34, 807-813.
39. Dokal, l., Jones, L., Deenmamode, M., Lewis, S.M. & Goldman, J.M. (1989) Allogeneic bone marrow transplantation for primary myelofibrosis. British Journal of Haematology, 71, 158-160.
40. Doki, N., Irisawa, H., Takada, S., Sakura, T. & Miyawaki, S. (2007) Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis. Internal Medicine, 46, 187-190.
41. Dupriez, B., Morel, P., Demory, J.L., Lai, J.L., Simon, M., Plantier, I. & Bautiers, F. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 1013-1018.
42. Elena, C., Passamonti, F., Rumi, E., Malcovati, L., Arcaini, L., Boveri, E., Merli, M., Pietra, D., Pascutto, C. & Lazzarino, M. (2011) Red blood ceell tranfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica, 96, 167-170.
43. Elliot, M.A., Chen, M.G., Silverstein, M.N. & Tefferi, A. (1998) Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 103, 505-511.
44. Faoro, L.N., Tefferi, A. & Mesa, R.A. (2005) Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. European Journal of Haematology, 74, 117-120.
45. Feldman, L.S., Demyttenacre, S.V., Polyhronopoulos, G.N. & Fried, G.M. (2008) Refining the selection critieria for laparoscopic versus open splenectomy for splenomegaly. Journal of Laparoendoscopic and Advanced Surgical Techniques, 18, 13-19.
46. + cells results in hematolgic responses - follow-up of three patients. Haematologica, 90, 17-20.
47. Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., Cervantes, F., Passamonti, F. & Tefferi, A. (2011) DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Journal of Clinical Oncology, 29, 392-397.
48. Gardner, F.H. & Besa, E.C. (1977) The onset of a refractory response to androgens in the anemia of bone marrow failure. Transactions of the American Clinical Climatological. Association, 88, 108-118.
49. Gilbert, H.S. (1998) Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer, 83, 1205-1213.
50. Guardiola, P., Esperou, H., Cazals-Hatem, D., Ifrah, N., Jouet, J.P., Buzyn, A., Sutton, L., Gratecos, N., Tilly, H., Lioure, B. & Gluckman, E. (1997) Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation. British Journal of Haematology, 98, 1004-1009.
51. Guardiola, P., Anderson, J.E., Bandini, G., Cervantes, F., Runde, V., Arcese, W., Bacigalupo, A., Przepiovka, D., O'Donnell, M.R., Polchi, P., Buzyn, A., Sutton, L., Cazals-Hatem, D., Sale, G., de Witte, T., Deeg, H.J. & Gluckman, E. (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood, 93, 2831-2838.
52. Guglielmelli, P., Pancrazzi, A., Bergamaschi, G., Rosti, V., Villiani, L., Antonioli, E., Bosi, A., Barosi, G. & Vannucchi, A.M. (2007) Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. British Journal of Haematology, 137, 244-247.
53. Guglielmelli, P., Barosi, G., Specchia, G., Rambaldi, A., Lo Coco, F., Antonioli, E., Pieri, L., Pancrazzi, A., Ponziani, V., Delaini, F., Longo, G., Ammatuna, E., Liso, V., Bosi, A., Barbui, T. & Vannucchi, A.M. (2009) Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood, 114, 1477-1483.
54. Guglielmelli, P., Biamonte, F., Score, J., Hidalgo-Curtis, C., Cervantes, F., Maffiolo, M., Fanelli, T., Ernst, T., Winkelmann, N., Jones, A.V., Zoi, K., Reiter, A., Duncombe, A., Villani, L., Bosi, A., Barosi, G., Cross, N.C. & Vannucchi, A.M. (2011) EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 188, 5227-5234.
55. Gupta, V., Kröger, N., Aschan, J., Xu, W., Leber, B., Dalley, C., Sabloff, M., Lipton, J.H., Messner, H. & Brune, M. (2009) A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplantation, 44, 317-320.
56. Harrison, C.N., Campbell, P.J., Buck, G., Wheatley, K., East, C.L., Bareford, D., Wilkins, B.S., van der Walt, J.D., Reilly, J.T., Grigg, A.P., Revell, P., Woodcock, B.E. & Green, A.R. (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine, 353, 33-45.
57. Harrison, C.N., Bareford, D., Butt, N., Campbell, P., Conneally, E., Drummond, M., Erber, W., Everington, T., Green, A.R., Hall, G.W., Hunt, B.J., Ludlam, C.A., Murrin, R., Nelson-Piercy, C., Radia, D.H., Reilly, J.T., Van der Walt, J., Wilkins, B. & McMullin, M.F. (2010) Guideline for the investigation and management of adults and children presenting with a thrombocytosis. British Journal of Haematology, 149, 352-375.
58. Harrison, C., Kiladjian, J.-J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A.M., Barbui, T. & Barosi, G. (2012) JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine, 366, 787-798.
59. Hast, R., Engstedt, L., Jaemeson, S., Killander, A., Lundh, B., Reizenstein, P., Skarberg, K.O., Uden, A.M. & Wadman, B. (1978) Oxymethalone treatment in myelofibrosis. Blut, 37, 19-26.
60. Hultdin, M., Sundström, G., Wahlin, A., Lundström, B., Samuelsson, J., Birgeegård, G. & Engström-Laurent, A. (2007) Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Medical Oncology, 24, 63-70.
61. Ianotto, J.-C., Kiladjian, J.-J., Demory, J.-L., Roy, L., Boyer, F., Rey, J., Dupriez, B., Berthou, C. & Abgrall, J.-F. (2009) PEG-IFN-α-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des Syndromes Myéloprolifératifs (FM). British Journal of Haematology, 146, 223-225.
62. Jabbour, E., Kantarjian, H., Cortes, J., Thomas, D.M., Garcia-Manero, G., Ferrajoli, A., Faderl, S., Richie, M.A., Beran, M., Giles, F. & Verstovsek, S. (2007) PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer, 110, 2012-2018.
63. Kerbauy, D.M., Gooley, T.A., Sale, G.E., Flowers, M.E., Doney, K.C., Georges, G.E., Greene, J.E., Linenberger, M., Petersdorf, E., Sandmaier, B.M., Scott, B.L., Sorror, M., Stirewalt, D.L., Stewart, F.M., Witherspoon, R.P., Storb, R., Appelbaum, F.R. & Deeg, H.J. (2007) Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera and essential thrombocythemia. Biology of Blood and Marrow Transplantation, 13, 355-365.
64. Kiladjian, J.J., Chomienne, C. & Fenaux, P. (2008) Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia, 22, 1990-1998.
65. Kröger, N., Holler, E., Kobbe, G., Bornhäuser, M., Schwerdtfeger, R., Baurmann, H., Nagler, A., Bethge, W., Stelljes, M., Uharek, L., Wandt, H., Burchert, A., Corradini, P., Schubert, J., Kaufmann, M., Dreger, P., Wulf, G.G., Einsele, H., Zabelina, T., Kvasnicka, H.M., Thiele, J., Brand, R., Zander, A.R., Niederwieser, D. & de Witte, T.M. (2009a) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 114, 5264-5270.
66. Kröger, N., Alchalby, H., Klyuchnikov, E., Badbaran, A., HIldebrandt, Y., Ayuk, F., Bacher, U., Bock, O., Kvasnicka, M., Fehse, B. & Zander, A. (2009b) JAK2-V617F-triggered premptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myeofibrosis after allogeneic stem cell transplantation. Blood, 113, 1866-1868.
67. Kupferschmid, J.P., Shahian, D.M. & Villanueva, A.G. (1993) Massive hemothorax associated with intrathoraxic extramedullary hematopoiesis involving the pleura. Chest, 103, 974-975.
68. Landolfi, R., Colosimo, C., De Candia, E., Castellana, M.A., De Cristofara, R., Trodella, L. & Leone, G. (1988) Meningeal hematopoiesis causing exophthalmos and hemiparesis in myelofibrosis: effect of radiotherapy. Cancer, 62, 2346-2349.
69. Leinweber, C., Order, S.E. & Calkins, A.R. (1991) Whole-abdominal irradiation for the management of gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia. Cancer, 68, 1251-1254.
70. Leitch, H.A., Chase, J.M., Goodman, T.A., Ezzat, H., Rollins, M.D., Wong, D.H., Badawi, M., Leger, C.S., Ramadan, K.M., Barnett, M., Foltz, L.M. & Vickars, L.M. (2010) Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation thhrapy. Hematolgical Oncology, 28, 40-48.
71. Levy, V., Bourgarit, A., Delmer, A., Legrand, O., Baudard, M., Rio, B. & Zittoun, R. (1996) Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. American Journal of Hematology, 53, 239-241.
72. Lissandre, S., Bay, J.-O., Cahn, J.-Y., Porcher, R., Cacheux, V., Cabrespine, A.J., Cornillon, J., Cassinat, B., Peffault de Latour, R., Socie, G. & Robin, M. (2011) Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. Bone Marrow Transplantation, 46, 557-561.
73. Löfvenberg, E. & Wahlin, A. (1988) Management of polycythaemia vera, essential thrombocythaemia and meylofibrosis with hydroxyurea. European Journal of Haematology, 41, 375-381.
74. López-Guillermo, A., Cervantes, F., Bruguera, M., Pereira, A., Feliu, E. & Rozman, C. (1991) Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. Acta Haematologica, 85, 184-188.
75. Manoharan, A. & Pitney, W.R. (1984) Chemotherapy resolves and reverses marrow fibrosis in myelofibrosis. Scandinavian Journal of Haematology, 33, 453-459.
76. Martinez-Trillos, A., Gaya, A., Maffioli, M., Arellano-Rodrigo, E., Calvo, X., Diaz-Beyá, M. & Cervantes, F. (2010) Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Annals of Hematology, 89, 1233-1237.
77. Mesa, R.A., Steensma, D.P., Pardanani, A., Li, C.Y., Elliott, M., Kaufmann, S.H., Wiseman, G., Gray, L.A., Schroeder, G., Reeder, T., Zeldis, J.B. & Tefferi, A. (2003) A phase 2 trial of combination low-dose thalidomide and prednisolone for the treatment of myelofibrosis with myeloid metaplasia. Blood, 101, 2534-2541.
78. Mesa, R.A., Li, C.Y., Ketterling, R.P., Schroeder, G.S., Knudson, R.A. & Tefferi, A. (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood, 105, 973-977.
79. Mesa, R.A., Verstovsek, S., Cervantes, F., Barosi, G., Reilly, J.T., Dupriez, B., Levine, R., Le Bousee-Kerdiles, M.C., Wadleigh, M., Campbell, P.J., Silver, R.T., Vannucchi, A.M., Deeg, H.J., Gisslinger, H., Thomas, D., Odenike, O., Solberg, L.A., Gotlib, J., Hexner, E., Nimer, S.D., Kantarjian, H., Orazi, A., Vardiman, J.W., Thiele, J. & Tefferi, A. (2007) Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leukemia Research, 31, 737-740.
80. Neben-Wittich, M.A., Brown, P.D. & Tefferi, A. (2010) Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. American Journal of Hematology, 85, 808-810.
81. Nivison-Smith, I., Dodds, A.J., Butler, J., Bradstock, K.F., Ma, D.D., Simpson, J.M. & Szer, J. (2011) Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk. Biology of Blood and Marrow Transplantation, 18, 302-308.
82. Pardanani, A.D., Levine, R.L., Lasho, T., Pikman, Y., Mesa, R.A., Wadleigh, M., Steensma, D.P., Elliott, M.A., Wolanskyj, A.P., Hogan, W.J., McClure, R.F., Litzow, M.R., Gilliland, D.G. & Tefferi, A. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108, 3472-3476.
83. Passamonti, F., Rumi, E., Pietra, D., Elena, C., Boveri, E., Arcaini, L., Roncovoni, E., Astori, C., Merli, M., Boggi, S., Pascutto, C., Lazzarino, M. & Cazzola, M. (2010a) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leucocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia, 24, 1574-1579.
84. Passamonti, F., Cervantes, F., Vannucchi, A.M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Caramella, M., Maffioli, M., Pascutto, C., Lazzarino, M., Cazzola, M. & Tefferi, A. (2010b) A Dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Party for Myeloproliferative Neoplasms Research and Treatment). Blood, 115, 1703-1708.
85. Patriarca, F., Bacigalupo, A., Sperotto, A., Isola, M., Soldano, F., Bruno, B., van Lint, M.T., Iori, A.P., Santarone, S., Porretto, F., Pioltelli, P., Visani, G., Iacopino, P., Fanin, R. & Bosi, A. (2008) Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica, 93, 1514-1522.
86. Patriarca, F., Bacigalupo, A., Sperotto, A., Isola, M., Bruno, B., van Lint, M.T., Iori, A.P., Di Bartolomeo, P., Musso, M., Pioltelli, P., Visani, G., Iacopino, P., Fanin, R. & Bosi, A. (2010) Outcome of allogeneic stem cell transplantation following reduced intensity conditioning regimen in patients with idiopathic myelofibrosis: the GITMO experience. Mediterranean Journal of Infectious Diseases, 2, 2.Haematologica, 93, 1514-1522.
87. Petti, M.C., Latagliata, R., Spadea, T., Spadea, A., Montefusco, E., Aloe Spiriti, M.A., Avvisati, G., Breccia, M., Pescarmona, E. & Mandelli, F. (2002) Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 116, 576-581.
88. Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., DeAngelo, D.J., Clark, J.J., Lee, S.J., Goloub, T.R., Wadleigh, M., Galliland, D.G. & Levine, R.L. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Medicine, 3, e270.
89. Price, F. & Bell, H. (1985) Spinal cord compression due to extramedullary hematopoiesis. Successful treatment in a patient with long standing myelofibrosis. JAMA, 253, 2876-2877.
90. Radin, A.I., Kim, H.T., Grant, B.W., Bennett, J.M., Kirkwood, J.M., Stewart, J.A., Hahn, R.G., Dutcher, J.P., Wiernik, P.H. & Oken, M.M. (2003) Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the eastern Cooperative Oncology Group. Cancer, 98, 100-109.
91. Riesterer, O., Gmür, J. & Lütolf, U. (2008) Repeated and preemptive palliative radiotherapy of symptomatic hepatomegaly in a patient with advanced myelofibrosis. Onkologie, 31, 325-327.
92. Rondelli, D., Barosi, G., Bacigalupo, A., Prchal, J.T., Popat, U., Alessandrino, E.P., Spivak, J.L., Smith, B.D., Klingemann, H.G., Fruchtman, S. & Hoffman, R. (2005) Allogeneic hematopoietic sten-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood, 105, 4115-4119.
93. Samuelson, S., Sandmaier, B.M., Heslop, H.E., Popat, U., Carrum, G., Champlin, R.E., Storb, R., Prchal, J.T., Gooley, T.A. & Deeg, J.H. (2011) Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. British Journal of Haematology, 153, 76-82.
94. Scherber, R., Dueck, A.C., Johansson, P., Barbui, G., Vannucchi, A.M., Passamonti, F., Andreasson, B., Ferarri, M.L., Rambaldi, A., Samuelsson, J., Birgegard, G., Tefferi, A., Harrison, C.N., Radia, D. & Mesa, R.A. (2011) The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood, 118, 401-408.
95. Scott, B.L., Gooley, T.A., Linenberger, M.L., Sandmaier, B.M., Myerson, D., Chauncey, T., Appelbaum, F.R. & Deeg, H.J. (2010) International Working Group scores predict post-transplant outcomes in patients with myelofibrosis. Blood, 116, 3085a.
96. Scott, B.L., Gooley, T.A., Sorror, M.L., Rezvani, A.R., Linenberger, M.L., Grim, J., Sandmaier, B.M., Myerson, D., Chauncey, T.R., Storb, R., Buxhofer-Ausch, V., Radich, J.P., Appelbaum, F.R. & Deeg, H.J. (2012) The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood, 119, 2657-2664.
97. Shahani, S., Braga-Basaria, M., Maggio, M. & Basaria, S. (2009) Androgens and erythropoiesis: past and present. Journal of Endocrinological Investigation, 32, 704-716.
98. Silver, R.T. & Vandris, K. (2009) Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis. Leukemia, 23, 1366-1369.
99. Silver, R.T., Jenkins, D.E. & Engle, R.L. (1964) Use of testosterone and busulfan in the treatment of myelofibrosis with myeloid metaplasia. Blood, 23, 341-353.
100. Soiffer, R.J., Lerademacher, J., Ho, L., Kan, F., Artz, A., Champlin, R.E., Devine, S., Isola, L., Lazarus, H.M., Marks, D.I., Porter, D.L., Waller, E.K., Horowitz, M.M. & Eapen, M. (2011) Impact of immune modulation with anti-T cell antibodies on the outcome of redcued-intensity allogeneic hematopoietic stem cell transplantaion for hematologic malignancies. Blood, 117, 6963-6970.
101. Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G. & Storer, B. (2005) Hematopoietic cell transplanation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106, 2912-2919.
102. Steensma, D.P., Hook, C.C., Stafford, S.L. & Tefferi, A. (2002) Low-dose, single fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis and myeloid metaplasia. British Journal of Haematology, 118, 813-816.
103. Stewart, W.A., Pearce, R., Kirkland, K.E., Bloor, A., Thomson, K., Apperley, J., McQuaker, G., Marks, D.I., Craddock, C., McCann, S., Russell, N., Cook, G. & Kottarides, P.D. (2010) The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplanation study. Bone Marrow Transplanation, 45, 1587-1593.
104. Takagi, S., Ota, Y., Uchida, N., Takahashi, K., Ishiwata, K., Tsuji, M., Yamamoto, H., Asano-Mori, Y., Matsuno, N., Masuoka, K., Wake, A., Miyakoshi, S., Ohashi, K. & Taniguchi, S. (2010) Successful engraftment after reduced-intensity umbical cord transplantation for myelofibrosis. Blood, 116, 649-652.
105. Tefferi, A., Mesa, R.A., Nagomey, D.N., Schroeder, G. & Silverstein, M.N. (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood, 95, 2226-2233.
106. Tefferi, A., Elliot, M.A., Yoon, S.Y., Li, C.Y., Mesa, R.A., Call, T.G. & Dispenzieri, A. (2001a) Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood, 97, 1896.
107. Tefferi, A., Jiménez, T., Gray, L.A., Mesa, R.A. & Chen, M.G. (2001b) Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. European Journal of Haematology, 66, 37-42.
108. Tefferi, A., Lasho, T.L., Schwager, S.M., Steensma, D.P., Mesa, R.A., Li, C.Y., Wadleigh, M. & Gilliland, G. (2005) The JAK2 (V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. British Journal of Haematology, 131, 320-328.
109. Tefferi, A., Barosi, G., Mesa, R.A., Cervantes, F., Deeg, H.J., Reilly, J.T., Verstovsek, S., Dupriez, B., Silver, R.T., Odenike, O., Cortes, J., Wadleigh, M., Solberg, L.A., Camoriano, J.K., Gisslinger, H., Noel, P., Thiele, J., Vardiman, J.W., Hoffman, R., Cross, N.C., Gilliland, D.G. & Kantarjian, H. (2006a) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood, 108, 1497-1503.
110. Tefferi, A., Cartes, J., Verstovsek, S., Mesa, R.A., Thomas, D., Lasho, T.L., Hogan, W.J., Litzow, M.R., Allred, J.B., Jones, D., Byrne, C., Zeldis, J.B., Ketterling, R.P., McClure, R.F., Giles, F. & Kantarjian, H.M. (2006b) Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood, 108, 1158-1164.
111. Tefferi, A., Lasho, T.L., Huang, J., Finke, C., Mesa, R.A., Li, C.Y., Wu, W., Hanson, C.A. & Pardanani, A. (2008) Low JAK2V617F allele burden in primary myelofibrosis compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia, 22, 756-761.
112. Tefferi, A., Pardanani, A., Lim, K.H., Abdel-Wahab, O., Lasho, T.L., Gangat, N., Finke, C.M., Schwager, S., Mullally, A., Li, C.Y., Hanson, C.A., Mesa, R., Bernard, O., Delhommeau, F., Vainchenker, W., Gilliland, D.G. & Levine, R.L. (2009a) TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia, 23, 905-911.
113. Tefferi, A., Mesa, R.A., Pardanani, A., Hussein, K., Schwager, S., Hanson, C.A. & Steensma, D.P. (2009b) Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased ferritin or transfusion load does not. American Journal of Hematology, 84, 265-267.
114. Thapaliya, P., Tefferi, A., Pardanani, A., Steensma, D.P., Camoriano, J., Wu, W., Geyer, S. & Mesa, R.A. (2011) International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisolone based regimens. American Journal of Hematology, 86, 96-98.
115. Thepot, S., Itzykson, R., Seegers, V., Raffoux, E., Quesnel, B., Chait, Y., Sorin, L., Dryfus, F., Cluzeau, T., Delaunay, J., Sanhes, L., Eclache, V., Dartigeas, C., Turlure, P., harel, S., Salanoubat, C., Kiladjian, J.J., Fenaux, P. & Adès, L. (2010) Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on behalf of the Group Francophone des Myelodyplasies (GFM). Blood, 116, 3735-3742.
116. Thiele, J., Kvasnicka, H.M., Tefferei, A., Barosi, G., Orazi, A. & Vardiman, J.W. (2008) Primary myelofibrosis. In: WHO Classification of tumours of Haematopoietic and Lymphoid Tissues (eds S.H. Swerdlow, E. Campo, N.L. Harris, E. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman ), pp. 44-47. IARC, Lyon.
117. Tulpule, S., Bewley, S., Robinson, S.E., Radia, D., Nelson-Piercy, C. & Harrison, C.N. (2008) The management and outcome of four pregnancies in women with idiopathic myelofibrosis. British Journal of Haematology, 142, 480-482.
118. Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., Marfisi, R.M., Finazzi, G., Guerini, V., Fabris, F., Randi, M.L., De Stefano, V., Caberlon, S., Tafuri, A., Ruggeri, M., Specchia, G., Liso, V., Rossi, E., Pogliani, E., Gugliotta, L., Bosi, A. & Barbui, T. (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, 110, 840-846.
119. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellström-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.
120. Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, Jr, J.H., Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Koumenis, I.L., Sun, W., Sandor, V. & Kantarjian, H.M. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366, 799-807.
121. Wiest, R., Strauch, U., Wagner, H., Strotzer, M., Woenckhaus, M., Schroder, G., Schölmerich, J. & Lock, G. (2004) A patient with myelofibrosis complicated by refractory ascites and portal hypertension: to tips or not to tips? A case report with discussion of the mechanism of ascites formation. Scandinavian Journal of Gastroenterology, 39, 389-394.
122. Wilkins, B.S., Erber, W.N., Bareford, D., Buck, G., Wheatley, K., East, C.L., Paul, B., Harrison, C.N., Green, A.R. & Campbell, P.J. (2008) Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood, 111, 60-70.
123. Zang, D.Y. & Deeg, H.J. (2009) Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Current Opinion in Hematology, 16, 140-146.